<DOC>
	<DOCNO>NCT00062894</DOCNO>
	<brief_summary>The purpose study assess blood pharmacokinetics patient previously untreated relapsed follicular transform follicular non-Hodgkin 's lymphoma receive dosimetric dose fission-derived iodine I 131 tositumomab .</brief_summary>
	<brief_title>Study Untreated Transformed Follicular Non-Hodgkin 's Lymphoma With Fission-Derived Iodine I 131 Tositumomab</brief_title>
	<detailed_description>This multi-center study 12 patient previously untreated relapsed follicular transform follicular non-Hodgkin 's lymphoma receive dosimetric dose fission-derived Iodine I 131 Tositumomab follow therapeutic dose tellurium-derived Iodine I 131 Tositumomab . Blood Pharmacokinetics , total body clearance , tumor organ dosimetry , biodistribution assess follow administration dosimetric dose .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>At least 18 year age Histologically confirm diagnosis follicular lymphoma , Grade 1 , 2 , 3 , diffuse large cell lymphoma ( WHO/REAL classification ) . Follicular , small cleave ; Follicular , mix small cleave large cell ; Follicular large cell lymphoma Transformed diffuse large cell lymphoma follow concurrent diagnosis follicular lymphoma . Stage III IV disease time study entry . Previously untreated recurrent lymphoma four prior qualify therapy regimen . Performance status least 70 % Karnofsky Performance Scale anticipate survival least three month . Bidimensionally measurable disease least one lesion measure great equal 2.0 cm x 2.0 cm ( =4.0 cm2 ) CT scan . Absolute B lymphocyte count ( determined CD 19 reactivity ) 30 350 cell/mm3 within 21 day prior study enrollment . ANC great equal 1500 cells/mm3 ; absolute lymphocyte count within normal limit ; platelet count great equal 150,000/mm3 within 21 day prior study enrollment . Blood product and/or growth factor take within 4 week prior blood draw . Adequate renal function ( define serum creatinine &lt; 1.5 x ULN ) hepatic function ( defined total bilirubin &lt; 1.5 x ULN AST &lt; 5 x ULN ) within 21 day study enrollment . Human AntiMurine Antibody ( HAMA ) negative within 21 day prior study enrollment . Signed IRB approve consent form prior studyspecific procedure implement . Greater 25 % intratrabecular marrow space involve lymphoma bone marrow biopsy specimen assess microscopically within 90 day study enrollment . Bilateral posterior iliac crest core biopsy require core obtain unilateral biopsy le 2 cm . Prior chemotherapy , biologic therapy , steroid , radiation therapy treatment NHL within 28 day prior study enrollment . Prior Rituximab therapy within 120 day prior study enrollment . Prior radioimmunotherapy . Prior splenectomy . Splenomegaly define spleen mass great 700 gram . Bulky disease define unidimensional measurement lymphomatous mass exceed 7 cm . Prior malignancy lymphoma , except adequately treated skin cancer , situ cervical cancer , cancer patient generally accept risk recurrence le 20 % . Central nervous system involvement lymphoma . Evidence active infection require IV antibiotic time study enrollment . Known HIV infection . New York Heart Association class III IV heart disease serious illness would preclude evaluation . Active obstructive hydronephrosis . Evidence clinically significant ascites pleural effusion observe screen physical exam baseline CAT xcan . Prior myeloablative therapy . History fail stem cell collection . Pregnant nursing patient . Patients childbearing potential must undergo serum pregnancy test within 7 day study enrollment radiolabeled antibody administer negative result obtain . Males females childbearing age , must agree use effective contraception six month follow radioimmunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Iodine I 131 Tositumomab</keyword>
	<keyword>BEXXAR</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
</DOC>